The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model

• Published in: Diabetes & vascular disease research Vol. 10; no. 4; pp. 353 - 360
• Main Authors: Gaspari, Tracey, Welungoda, Iresha, Widdop, Robert E, Simpson, Richard W, Dear, Anthony E
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.07.2013
• Subjects: Animals; Apolipoproteins E - deficiency; Apolipoproteins E - metabolism; Atherosclerosis - diagnosis; Atherosclerosis - drug therapy; Diabetes Mellitus, Type 2 - drug therapy; Disease Models, Animal; Disease Progression; Endothelial Cells - drug effects; Glucagon-Like Peptide 1 - analogs & derivatives; Glucagon-Like Peptide 1 - therapeutic use; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents - therapeutic use; Liraglutide; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic - diagnosis; Plaque, Atherosclerotic - drug therapy; Receptors, Glucagon - agonists; liraglutide; atherosclerosis; Incretin; endothelial dysfunction; glucagon-like peptide-1; plaque stability

Liraglutide, a once-daily glucagon-like peptide-1 receptor (GLP-1R) agonist, has been approved as a new treatment for type 2 diabetes and is the subject of a clinical trial programme to evaluate the effects on cardiovascular disease and safety. The current study aimed to determine the in vivo effect...